“We believe in the promise of the resurgence of psychedelic medicine and are proud to be collaborating with Lobe Sciences as we work together to improve the lives and health of members of the WBA family,” says WBA president Gilberto Jesús Mendoza.
This week in psychedelic business news: more evidence supporting ketamine for depression; a new use for MDMA; Lobe Sciences makes a leap in treating PTSD; Delix raises big bucks; and BetterLife Pharma patents solution for cluster headaches.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.